In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
2009 2009: Minimum TRIPS Terms of Protection for Copyright and Related Rights 2009: TransAtlantic Consumer Dialogue (TACD) resolution on copyright terms 2009: Terms of Protection for Copyright and Related Rights in multilateral treaties 2012 2012: Republican Study Committee report suggests… Continue Reading
In the area of Transparency, KEI works on several different topics, including for example: Norm setting. KEI has advocated access to meeting venues, timely disclosures of negotiating texts, and the use of webcasting of meetings, among other measures. Trade negotiations… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
The USTR’s Special 301 Report has been issued every year beginning in 1989. The Executive Summary of the 2009 report says: The “Special 301” Report is an annual review of the global state of intellectual property rights (IPR) protection and… Continue Reading
We have a complete collection of USTR 301 Reports here: The USTR Special 301 Reports, 1989 to 2024 National Trade Estimate Report on Foreign Trade Barriers (the annual NTE reports) Below are a few more USTR links, but you can… Continue Reading
On December 13, 2017, a joint statement on e-commerce was endorsed by Ministers representing 70 WTO members at the 11th WTO Ministerial Conference in Buenos Aires, Argentina (see below). KEI’s statement on the WTO e-commerce agenda is as follows: “There… Continue Reading
On Friday, 20 October 2017, Brazil delivered the following statement during TRIPS Council discussions on compulsory licensing. Brazil zeroed in a recent compulsory licensing case in Germany involving raltagravir, an antiretroviral.
On 20 October 2017, South Africa delivered the following statement on behalf of Brazil, China, India, and South Africa during the WTO TRIPS Council’s discussions on compulsory licensing. On 31 May 2017, these delegations (along with Fiji) submitted a proposal to the TRIPS Council on “Intellectual Property and the Public Interest” which would serve as an overarching theme for the Council to address issues including access to knowledge and access to medicines. Continue Reading